MAP2 and Alzheimer disease: When normalized to ß-actin and MAP2, α1-chimaerin mRNA levels in the AD cases were reduced to 37.3% and 31.3%, respectively, compared to control levels (P < 0.01, Table 2 and Fig. 3A).